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Abstract
Background: Coat protein complex 1 (COPI) is integral in the sorting and retrograde trafficking of proteins and
lipids from the Golgi apparatus to the endoplasmic reticulum (ER). In recent years, coat proteins have been
implicated in human diseases known collectively as “coatopathies”.
Methods: Whole exome or genome sequencing of two families with a neuro-developmental syndrome, variable
microcephaly and cataracts revealed biallelic variants in COPB1, which encodes the beta-subunit of COPI (β-COP). To
investigate Family 1’s splice donor site variant, we undertook patient blood RNA studies and CRISPR/Cas9 modelling
of this variant in a homologous region of the Xenopus tropicalis genome. To investigate Family 2’s missense variant,
we studied cellular phenotypes of human retinal epithelium and embryonic kidney cell lines transfected with a
COPB1 expression vector into which we had introduced Family 2’s mutation.
Results: We present a new recessive coatopathy typified by severe developmental delay and cataracts and variable
microcephaly. A homozygous splice donor site variant in Family 1 results in two aberrant transcripts, one of which
causes skipping of exon 8 in COPB1 pre-mRNA, and a 36 amino acid in-frame deletion, resulting in the loss of a
motif at a small interaction interface between β-COP and β’-COP. Xenopus tropicalis animals with a homologous
mutation, introduced by CRISPR/Cas9 genome editing, recapitulate features of the human syndrome including
microcephaly and cataracts. In vitro modelling of the COPB1 c.1651T>G p.Phe551Val variant in Family 2 identifies
defective Golgi to ER recycling of this mutant β-COP, with the mutant protein being retarded in the Golgi.
Conclusions: This adds to the growing body of evidence that COPI subunits are essential in brain development
and human health and underlines the utility of exome and genome sequencing coupled with Xenopus tropicalis
CRISPR/Cas modelling for the identification and characterisation of novel rare disease genes.
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Background
The endomembrane system is composed of a group of
organelles (including the endoplasmic reticulum (ER),
Golgi apparatus and endoplasmic reticulum-Golgi inter-
mediate compartment (ERGIC)). It allows modification,
packaging and transport of proteins through the
secretory pathway in eukaryotic cells [1]. Proteins move
between different organelles in membrane-bound
transport vesicles coated with proteins. Protein coat
complexes include coatomer protein I (COPI) complex,
coatomer protein II (COPII) complex, a number of
adaptor protein (AP) complexes including clathrin
adaptor protein complexes, and the retromer complex
[2]. These protein coats select cargo (proteins and lipids)
for transport and facilitate transport vesicle formation.
The functioning of protein coats is a fundamental cellu-
lar process. Knockout of certain subunits of COPI and
COPII, such as COPB2, in mice is embryonic lethal [3,
4]. Depletion of COPI in cancer cells results in decreased
cell survival, impaired autophagy and ER stress [5].
COPI consists of seven subunits (α, β (the focus of this
study), β’, γ, δ, ε and ζ) (Fig. 1a) [6]. The COPI subunits
can be divided into the F- (or Adaptor-like) subcomplex
(containing the β, γ, δ and ζ subunits) and the B- (or
Cage-like) subcomplex (α, β′ and ε) (Fig. 1a) [7–9]. The
adaptor-like subcomplex, which contains β-COP, is
analogous to the clathrin adaptor AP subcomplexes [10].
Both β-COP and γ-COP contain an α-solenoid “trunk”
domain, connected by a linker to a small appendage do-
main [11].
ARF1, a small GTPase, catalyses COPI recruitment to
the vesicle. When GTP-bound, ARF1 becomes stabilised
in the membrane and initiates recruitment of COPI
through binding with the trunk domains of the β-COP
and γ-COP subunits [13]. COPI causes increased curva-
ture of the membrane, until a vesicle forms and scission
occurs [14]. After the vesicle is released, the COPI coat
is shed and ARF1 and COPI can dissociate (Fig. 1b).
The primary functions of COPI are returning ER-
resident proteins back from the Golgi to the ER, recyc-
ling certain transmembrane cargo receptors from the
cis-golgi and ERGIC, and intra-Golgi retrograde trans-
port [15]. COPI is also involved in lipid droplet forma-
tion and lipolysis [16]. Depletion of β-COP results in
defective cargo transport and defective compartmental-
isation of the ERGIC trans-Golgi network, Golgi, and re-
cycling endosomes, emphasising its importance in both
compartmentalisation and transport [17].
As with other coat protein complexes, several elements
of the COPI machinery have been linked to human
disease. The term “coatopathies” has been suggested to
describe this heterogenous group of conditions (Fig. 1a)
[2]. Homozygous variants in COPB2 have been linked to
a severe microcephaly syndrome (MIM # 617800) [4].
The COPI complex may also play a role in Alzheimer
disease as it is involved in the localisation of amyloid
precursor protein and silencing of δ-COP leads to de-
creased amyloid plaques and improved memory in mice
[18]. Interestingly, loss-of-function mutations in ARCN1
(which encodes δ-COP) cause a distinctive syndrome of
craniofacial abnormalities, microcephalic dwarfism and
mild developmental delay (MIM # 617164) [19]. Loss-of-
function variants in COPA cause an autoimmune dis-
order of arthritis and lung disease (MIM # 616414) [20,
21]. Hypomorphic variants in ARF1 (which though not
part of COPI, interacts closely with it, as described
above) have been linked to brain malformations includ-
ing periventricular heterotopia (MIM # 618185) [22]. β-
COP has never been associated with Mendelian disease.
This study aimed to identify the molecular cause of a
syndromic presentation in two unrelated families and in-
vestigate the pathogenicity of putative variants. We de-
scribe a new genetic disorder identified in six individuals
across two families associated with biallelic variants in
COPB1. This syndrome is typified by a severe intellec-
tual disability with variable microcephaly and cataracts.
Methods
Subjects and sequencing
As part of clinical care, Exeter Clinical Laboratory per-
formed whole exome sequencing on lymphocyte-
extracted DNA from a duo of two affected sisters from
Family 1. This involved exome sequence analysis of the
coding region and conserved splice sites of 23,244 genes
by next-generation sequencing (Twist Core Human Ex-
ome/Illumina NextSeq). The duo analysis utilised a
gene-agnostic approach to identify rare homozygous or
compound heterozygous variants shared by both sisters.
Segregation analysis of a candidate variant was under-
taken on lymphocyte-extracted DNA from all family
members in keeping with routine clinical practice. As
this investigation identified a splicing variant in a non-
morbid gene, the participants were recruited to a re-
search study to investigate the functional effect of these
variants using lymphocyte-extracted RNA. Patient enrol-
ment took place at University Hospital Southampton
UK.
Family 2 were recruited as part of a multicentre clin-
ical genome study in consanguineous Saudi populations
[23]. Whole genome sequencing was performed on
lymphocyte-extracted DNA and data was analysed with
both gene-agnostic and gene panel approaches. The en-
rolment, data collection and analysis were conducted at
King Abdulaziz Medical City, Riyadh, Saudi Arabia. Data
collection was performed by analysing results from elec-
tronic health records. WGS was carried in clinical CAP/
CLIA-accredited laboratories as part of a collaborative
project. WGS was performed using HiSeq 4000. This
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family was identified with use of the GeneMatcher plat-
form [24].
Analysis of splice site variant
In silico analysis
The prediction tools, Human Splicing Finder, Splice Site
Prediction by Neural Network, MaxEntScan and Spli-
ceAI, were used to predict the impact of Family 1’s vari-
ant on splicing [25–28].
Reverse transcriptase PCR (RT-PCR)
The effect of Family 1’s variant on splicing was investi-
gated using RT-PCR. Blood from the probands, parents
and unaffected siblings was collected in PAXgene® Blood
RNA Tubes (PreAnalytiX, Hombrechtikon, Switzerland).
RNA was then extracted from blood samples using the
PAXgene blood RNA kit (PreAnalytiX, Hombrechtikon,
Switzerland) and quality control was performed using a
2100 Bioanalyzer Instrument (Agilent, Santra Clara,
USA). RNA extracted from blood samples was converted
to cDNA using the High-Capacity cDNA Reverse Tran-
scription Kit (Thermo Fisher Scientific, Waltham, USA).
The primer pairs were designed using Primer 3 and
ordered from Integrated DNA Technologies (IDT,
Coralville, USA) (COPB1_ c957+1G>T_F_CTGGTGAA
TGAGAAGGATGCA, COPB1_c957+1G>T_R RV=GGC
TTCACGAACAAACTCCA).
PCR experiments were performed using GoTaq G2
Polymerase PCR system (Promega, Madison, USA) and
separated by agarose gel electrophoresis. The amplicons
were then documented under Chemidoc XRS+ (Bio-Rad,
Hercules, USA). The amplicons for further analysis were
cloned into plasmids using a TA cloning kit, with pCR
2.1 vector (Thermo Fisher Scientific, Waltham, USA).
The plasmids carrying inserts were sent to Source Bio-
science (Nottingham, UK) for Sanger sequencing.
Fig. 1 Structure and function of the COP1 complex. a COPI consists of a scaffold “B-subcomplex” (blue) and an adaptor “F-subcomplex” (green).
When GTP-bound, two ARF1 small GTPase molecules associate with the membrane and bind COPI via the β-COP and γ-COP subunits. A number
of subunits of this complex have been implicated in human disease as shown. b COPI complexes and their ARF1 molecules associate into triads.
Cargo, such as ER-resident proteins which need to be returned from the Golgi, are selected by binding directly with COPI subunits or indirectly
through transmembrane receptors which in turn bind with COPI. COPI polymerises on the membrane enabling its deformation/curvature, and
eventually budding and scission of the transport vesicle. When released, the vesicle’s coat is shed and ARF1 and COPI dissociate. Adapted from
Nickel et al. [12]
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Xenopus care
Nigerian strain Xenopus tropicalis were housed and
maintained within the European Xenopus Resource
Centre, University of Portsmouth, in re-circulating sys-
tems (25 °C) with 15% daily water changes on a 13–11-h
light-dark cycle. All procedures were conducted in ac-
cordance with the Home Office Code of Practice, under
PPL 70/8983 with approval from the University of Ports-
mouth’s Animal Welfare and Ethical Review Body.
Adult female X. tropicalis were primed the evening
prior to egg collection with 10 IU hCG (Chorulon, Inter-
vet) and received a boosting dose of 100 IU hCG the fol-
lowing morning. Egg clutches were obtained by gentle
abdominal massage and fertilised with cryopreserved
sperm. Frozen X. tropicalis spermatozoa were generated
within the European Xenopus Resource Centre from 12-
to 15-month-old male X. tropicalis exhibiting enhanced
nuptial pads. Sperm cryopreservation followed a proto-
col adapted from Sargent and Mohun [29].
Generating knockout animals using CRISPR-Cas9
The exon structure of the copb1 gene in X. tropicalis
and humans is identical despite the difference shown
currently on Xenbase’s gene page; we identified an un-
translated exon contributing to the 5′ UTR of the gene
by using its conservation with X. laevis. The target re-
gion within copb1 exon 8 was identified using Xenbase
(originally designed against v9.1 of the genome and
checked against v10) [30], and two single-stranded oligo-
nucleotides were selected based on the following criteria:
high mutagenic activity, minimal predicted off-target






Single guide RNAs (sgRNA) were synthesised from
single-stranded oligonucleotides (Invitrogen, above) con-
taining the T7 promoter as described in the Taq-based
method by Nakayama et al., using the T7 megashort-
script kit (Invitrogen) [33]. sgRNAs were subsequently
purified (SigmaSpin post-reaction clean up columns)
and visualised by agarose gel electrophoresis. The quan-
tity and purity were assessed using a NanoDrop 1000
spectrophotometer and sgRNAs were stored at − 80 °C
as single use aliquots. Each sgRNA (500 pg) was co-
injected with Cas9 protein (2.6 ng, spy Cas9 NLS, NEB)
at 1-cell and 2-cell stages into X. tropicalis embryos
from both a wild-type strain and a transgenic line
([Xtr.Tg (tubb2b:GFP)Amaya] RRID:EXRC_3001) [34].
Although we show un-injected control tadpoles, these
experiments were performed alongside CRISPR-based
knockouts of other genes and the phenotypes shown
here were specific to the copb1 sgRNA(s).
To determine the efficiency of indel formation, the tar-
get region of interest was amplified from genomic DNA
(Lysis Buffer: 50 mM Tris (pH 8.5), 1 mM EDTA, 0.5%
[v/v] Tween-20, 100 μg/ml Proteinase K) by polymerase
chain reaction, using primers designed in Primer3
(http://primer3.ut.ee; Exon8 FWD: TGTGTCCCTA
GGCAGCCG, Exon8 REV: CGAGGACACCAGTTCC
AGT).
A T7 Endonuclease I (NEB) assay was used to indicate
success of indel formation and this was confirmed using
Sanger sequencing (Genewiz) [34, 35]. Due to the results
seen as a consequence of the Family 1 mutation, we
tested whether exon skipping had occurred in these
samples. cDNA was prepared using Tristar solution [36]
from control and crispant tadpoles; PCR products (amp-
lified using primers spanning Exon6-7:CTACAAGGTT
TGCCATGCCAAC and Exon9-10:GATGACCAGC
TCTTCCACGTTG) were subcloned into pGEMTeasy
and compared by Sanger sequencing (Genewiz).
Phenotypic analysis of knockout tadpoles
Gross morphological differences between un-injected
tadpoles and crispant tadpoles were identified using a
Zeiss Axio Zoom.V16 Stereomicroscope (with fluores-
cence for GFP-expressing animals). Detailed structural
differences were examined by high-resolution micro-
computed tomography (MicroCT). For bright-field/
fluorescence microscopy, tadpoles were anaesthetised in
0.025% MS222, whilst tadpoles for MicroCT were fixed
in paraformaldehyde following the method described for
wholemount in situ hybridisation of Xenopus embryos
[37]. These fixed specimens were immediately contrast
stained in phosphotungstic acid (PTA) following an
adapted protocol from Metscher [38]. Briefly, samples
were stained in 1% PTA (in water) for 24 h, washed in
methanol and placed in 1% PTA for a further 24 h. Spec-
imens were allowed to rest in methanol for 1 week, be-
fore samples were embedded in 0.7% agarose within a
20 μl pipette tip (to prevent movement during imaging).
Samples were imaged using the ZEISS Xradia Versa 520
(Carl Zeiss Microscopy, Pleasanton, CA, USA) set to op-
erate at a voltage of 50 kV and a current of 75 mA. A
× 4 objective lens was used, resulting in an effective iso-
tropic voxel size of 3.1 μm. In total, 1601 projections
were collected over 360° with an exposure time of 2.0 s
per projection. Each tomogram was reconstructed to 16-
bit grey-level images using the manufacturer’s software
(Scout and Scan Reconstructor, Carl Zeiss Microscopy,
Pleasanton, CA, USA) which employs a filtered back
projection algorithm. The imaged volumes were then
visualised using TXM3DViewer (Carl Zeiss Microscopy,
Pleasanton, CA, USA).
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Analysis of missense variants
In silico analysis
SIFT, PolyPhen 2 and CADD tools were used to predict
the impact of Family 2’s variant on β-COP protein struc-
ture and function [39–42]. Conservation at the nucleo-
tide level was assessed using the PhyloP score which
attempts to measure deviation from the neutral rate of
substitution including conservation and acceleration
[43]. ConSurf conservation scores were used to measure
the evolutionary rate of the amino acid [44]. PyMOL
(Schrodinger) package was used to model the effect of
the missense variant on the 3D structure of β-COP in
complex with other components of COPI coat complex
with the ArfGAP2 uncoating factor (pdb file 5NZS).
Site-directed mutagenesis of COPB1 constructs
Specific patient mutation was introduced into a Myc-DDK-
tagged COPB1 transcript 1 (NM_016451) expression vector
(Origene, MD, USA) using the Q5 Site-Directed Mutagen-
esis Kit (New England BioLabs, MA, USA) following manu-
facturer’s instructions with customised primers designed
using NEB Base Changer [45] (COPB1_ c.1651_T>G _F
GGATGGAGATgTCTTTGTTGC, COPB1_ c.1651_T>G
_R AGAAGGAATCCTCTCAAG).
Plasmids were purified using the QIAprep Spin Mini-
prep Kit (Qiagen, Hilden, Germany) and successful
mutagenesis was confirmed with Sanger sequencing by
Source Bioscience (Nottingham, UK) using custom
sequencing primers (COPB1_c.1651_T>G TGAGGC
ACAGGGAAATTCGA).
Transfection-grade plasmid preparation was then per-
formed with the QIAprep Spin Midiprep Kit (Qiagen,
Hilden, Germany).
Culture of human cell lines
hTERT RPE-1 cells (immortalised human retinal pig-
mentary epithelial cells (American Type Culture Collec-
tion, Manassas, VA, USA)) were maintained in a 50/50
mix of Dulbecco’s Modified Eagles Medium (DMEM)
and Ham’s F12 (DMEM/F12) at 37 °C 5% CO2. Human
embryonic kidney 293 cells (HEK 293 cells (American
Type Culture Collection, Manassas, VA, USA)) were
maintained in high glucose DMEM at 37 °C 5% CO2.
Nucleofection/transfection of cell lines
hTERT-RPE1 cells were nucleofected with mutant plas-
mid or wild type (WT) plasmid using the Nucleofector
4D (Lonza) and P3 kit (Lonza), following manufacturer’s
instructions. HEK293 cells were transfected with mutant
or WT plasmid using PEI.
Immunofluorescence staining and confocal imaging
Forty-eight hours after nucleofection, hTERT-RPE1 cells
were incubated for 30 min with 5 μM BODIPY-TR-
ceramide (Thermo Fisher Scientific, Waltham, MA,
USA) complexed with bovine serum albumin (BSA) in
phosphate-buffered saline (PBS) prepared following
manufacturer’s instructions. After 30 min, cells were
rinsed with ice-cold DMEM/F12 and incubated with
fresh medium at 37 °C 5% CO2 for a further 30 min.
Cells were fixed with 4% paraformaldehyde, blocked with
1% (w/v) non-fat milk powder/PBS and co-stained with
mouse anti-c myc antibody (clone 9E10, Sigma Aldrich)
and nuclear stain (DAPI (4′,6-diamidino-2-phenylindole)
(Thermo Fisher Scientific, Waltham, MA)), and Alexa-
Fluor secondary antibodies (Invitrogen). Alternatively,
cells were fixed in ice-cold methanol at − 20 °C for 5
min, permeabilised with 0.1% (v/v) Triton X-100/PBS at
room temperature for 5 min, blocked with 1% (w/v)
non-fat milk powder/PBS and immunostained with
rabbit anti giantin (ab37266, Abcam) and mouse anti-β-
COP (ab2899, Abcam) or rabbit anti SERPINH1
(HPA029198, Atlas Antibodies) and mouse anti-c myc
antibody (clone 9E10, Sigma Aldrich) and nuclear stain
(DAPI (4′,6-diamidino-2-phenylindole) (Thermo Fisher
Scientific, Waltham, MA)) and AlexaFluor secondary
antibodies (Invitrogen). Cells were imaged using con-
focal microscopy (Leica TCS SP5 Confocal Laser Scan-
ning Microscope with LASX software). Images were
processed in Adobe Photoshop and figures assembled in
Adobe Illustrator.
SDS PAGE and western blotting
Forty-eight hours after transfection, HEK293 cells were
treated with 10 μg/ml cycloheximide for 16 h. Cells were
then lysed with NP40 lysis buffer and total protein levels
were assessed using protein assay (DC Protein Assay,
Bio-Rad Laboratories, Hercules, CA, USA). Fifteen
microgrammes of total protein per sample was loaded
onto a 4–12% Bis-Tris polyacrylamide gel and proteins
separated by electrophoresis at 200 V for 1 h. Proteins
were transferred to PVDF membrane, blocked with 1%
non-fat dry milk powder/PBS. COPB1-cmyc was de-
tected using mouse anti-c-myc antibody (clone 9E10,
Sigma Aldrich) and beta actin (control) was detected
using anti-beta actin antibody (clone AC15, Sigma Al-
drich). HRP-conjugated secondary antibodies were used
and immunobands visualised with SuperSignal West
Femto reagent (Pierce) on a Chemidoc XRS+ (Bio-Rad,
Hercules, USA). Densitometry analysis was performed in




Family 1 are of Roma ethnicity (Fig. 2a). Patient IV2 was
the product of an uncomplicated pregnancy and was
born at term weighing 3.25 kg (0.2 SD, 50th centile).
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Fig. 2 Pedigrees and clinical presentation of individuals with COPB1 mutations. a Family 1 includes two affected individuals IV2 and IV3.
Individuals IV5, IV6 and IV7 are also suspected to have been affected with microcephaly and developmental delay. They died in early childhood
and no further details were available. IV2 and IV3 have minor dysmorphism with up-slanting palpebral fissures. b Family 2 includes four affected
individuals from two nuclear families all from the same Saudi tribe. c Gel electrophoresis of RT PCR amplicons in Family 1 demonstrates 2 bands
in the homozygous state (IV2, an affected individual) and in the heterozygous state (III1, an unaffected parent). d Electropherograms of band A
and band B from the heterozygous parent and homozygous proband. In the proband’s trace, a G has effectively been deleted due to the
creation of a new donor site by the G>T mutation. In band B, Exon 8 has been skipped (proband and parent)
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Antenatal ultrasounds and maternal health were normal.
During the neonatal period, she was noted to have torti-
collis and required physiotherapy. Breastfeeding was
normal. She had low tone and came to medical concern
at age 8 months as she was not sitting or smiling. Her
early milestones were severely delayed (Table 1). She can
now go up and down stairs but cannot climb. Her first
words were very delayed, occurring at 3 years of age
(“Mama”). Her language has subsequently improved and
she can speak in short phrases and follow two-step com-
mands. Her speech is unclear but understandable for
family members. Her head circumference is − 2.6 stand-
ard deviations (SD). Socially she is fully dependant on
her parents (Table 1).
She has a history of recurrent upper respiratory tract
infections and tonsillitis. A sleep study was performed
Table 1 Growth and development
Family
Family 1 Family 2
Ethnicity Roma (Polish) Arab (Saudi)





Patient ID IV2 IV3 IV7 IV8 IV9 IV4
Sex F F F F F F
Age at physical
assessment
14y 16y 15y 15y 11y 7y
OFC − 2.6 SD − 3.2 SD − 2 SD − 0.2 SD − 7.9 SD − 4.4 SD
Weight + 2.4 SD + 2.8 SD − 3.1 SD − 2.8 SD − 3.9 SD − 3.2 SD
Height − 0.1 SD − 1.9 SD − 1.8 SD − 1.2 SD + 0.6SD − 2.2 SD
Neonatal issues Hypotonia,
torticollis
























































18y 16y 17y 15y 11y 11y
Intellectual
disability











No speech Language “fair” No speech Limited speech




Uses wheelchair Uses wheelchair Unable to sit or
stand












Unable to perform self-care
Incontinent of urine and
faeces
Fully dependant Fully dependant Fully dependant Fully dependant
Shows subjects’ growth and development. Five of six subjects had microcephaly (− 2 SD); 3/6 had severe microcephaly (> 3SD). Patients in Family 1 developed
disproportionate weight to height and a “metabolic syndrome” phenotype (see Table 2). In contrast, in Family 2, subjects were underweight. All participants have
a severe intellectual disability. Gross motor abilities are variable with one participant in family 1 able to walk up stairs and two participants in Family 2 unable
to sit
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for snoring and pauses in breathing during sleep; this
was normal. Initial eye exams were normal. A left-sided
nuclear sclerotic cataract was first noted at age 13 years
and was associated with the development of a dense am-
blyopia. A divergent squint was also noted at this time.
Menarche was early at 9 years of age. Later in childhood,
she developed increased appetite, weight gain, acanthosis
nigricans (axillary) and facial hypertrichosis. She has no
history of seizures, and CT brain was normal in infancy.
Patient IV3 was also the product of an uncomplicated
pregnancy with normal antenatal imaging. She had low
tone during the neonatal period. Breast feeding was nor-
mal. As with her sister, her early milestones were se-
verely delayed. Her gait is described as unsteady and she
has difficulty with stairs. She has planovalgus foot de-
formity of one foot which is managed with orthopaedic
footwear. She was noted to have congenital deafness
with 65–90-dB hearing loss associated with a homozy-
gous GJB2 c.71G>A variant. She has absent speech. She
has difficulty communicating her needs especially pain.
She understands some simple commands, such as “give
it to me”. Initial eye exams were normal. She was noted
to have bilateral cataracts at age 7 years which was
treated with lens aspiration and intraocular implants at
age 8 years. Her vision is normal. Her microcephaly is
more severe than her sister’s and currently measures −
3.2 SD.
She developed focal seizures at 14 years. Her interictal
EEG was normal, and seizures are controlled with leveti-
racetam. Menarche occurred at 11 years. As with her sis-
ter, she developed increased appetite, increased weight,
facial hypertrichosis and axillary acanthosis nigricans
later in childhood.
In addition to IV2 and IV3, three first cousins had
microcephaly, developmental delay and died early in
childhood (IV5, IV6, IV7). No further phenotypic infor-
mation was available and genetic testing could not be
undertaken.
Table 2 Medical information
Family
Family 1 Family 2








Patient ID IV2 IV3 IV7 IV8 IV9 IV4
Eye disease Unilateral nuclear sclerotic
cataract noted at 13y with
dense amblyopia
Divergent squint
Bilateral cataracts noted age 7y, lens
















early menarche age 9y
Raised BMI





Focal seizures at age 14y, EEG



















high narrow palate, tapering
fingers
Up-slanting palpebral fissures, high
narrow palate, tapering fingers
Not
available
Not available Not available Not
available
Skin Large café au lait, striae
distensae






Kyphosis and mild scoliosis
Migraine
Plano valgus foot deformity
Kyphosis
All subjects from Family 1 and Family 2 developed cataracts. Subjects from Family 1 developed a metabolic syndrome with obesity, hirsutism and insulin
resistance or diabetes. Though no major abnormalities were identified on brain imaging, some individuals have neurological symptoms with seizures in one
participant (Family 1) and spasticity being present in Family 2. Family 2 also have an immunodeficiency with lymphopenia and inadequate antibody
response titres
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In terms of dysmorphology, both IV2 and IV3 have
up-slanting palpebral fissures, narrow palates and taper-
ing fingers.
Family 2
Family 2 includes four affected individuals from two nu-
clear families, all from the same Saudi tribe (Fig. 2b).
Prenatal and early neonatal information was not avail-
able for this family as subjects were born outside of the
hospital. All four individuals have severe intellectual dis-
ability. Language impairment is variable in this family
(individual IV8 is described as verbally fair at 15 years,
IV4 has limited verbal output at 11 years whereas IV9
and IV7 have no language at 17 and 11 years of age re-
spectively). All individuals have severe social impairment
and are fully dependant for personal care. IV9 and IV4
have severe microcephaly (> − 3 standard deviations). All
four affected individuals have developed cataracts and
patient IV9 has had surgical treatment for this. Affected
individuals in this family also have poor mobility. They
have developed spasticity and have delayed motor skills.
IV7 and IV8 use a wheelchair whereas IV9 and IV4 can-
not sit or stand. IV9 has dystonia.
Immunodeficiency was also identified in Family 2 with
severe lymphopenia being present in all four patients.
Specifically, T cell lymphopenia was present with very
depressed CD3+CD4+ cells. Immunoglobulin levels were
normal overall; however, the patients failed to mount
antibody responses to any specific antigens tested.
Panel-based genetic testing as part of routine clinical
care for known causes of severe combined immunodefi-
ciency did not reveal any putative causal variants of this
symptom. More detail on this feature is supplied in Add-
itional file 1: Table S1.
Dysmorphology information/clinical photographs were
not available for this family.
Genetic findings
Family 1
Family 1 are known to carry a 12;13 insertional trans-
location of approximately 761 Kb in size. This is present
in a balanced form in individual III2 and individual IV2,
as a duplication of chromosome 13q13.3 in individuals
IV3 and IV1 (who is phenotypically normal) and as a de-
letion in 13q3.3 in individual IV4 (who is phenotypically
normal). The copy number variant includes TRPC4
(MIM * 603651) which has not been linked to mono-
genic disease and UFM1 (MIM * 610553). Both the
deletion and duplication have been classified as likely
benign by a clinical laboratory. IV2 was found to have a
homozygous GJB2 c.71G>A variant, established as the
cause of her deafness. Gene panel testing for microceph-
aly (PanelApp Cataracts v2.2, PanelApp Severe
Microcephaly v1.47) and cataracts performed on a clin-
ical basis did not reveal a cause for the family’s
phenotype.
Whole exome sequencing showed no biallelic pre-
dicted pathogenic variants in any known disease genes.
(In total, 18 homozygous variants across 17 genes were
identified. The candidate variants and their interpret-
ation are supplied in Additional file 1: Table S2.) Further
review of variants in non-MIM annotated genes identi-
fied a homozygous c.957+1G>T variant in COPB1,
which affects the + 1 position of the donor site of exon 8
(Chr11(GRCh37):g.14504577C>A). Parents and un-
affected siblings were all found to be carriers of this vari-
ant, and IV2 and IV3 are homozygous. Four predictive
tools were in agreement, all in suggesting donor site loss
[25–28]. SpliceAI additionally predicted a new donor site
would be created 1 nucleotide before the WT exon 8
donor site, resulting in a 1 nucleotide frameshift
(Table 3).
Modelling of the mutation onto the 3D structure of β-
COP protein in complex with other components of the
COPI coat leaf in complex with the ArfGAP2 uncoating
factor (pdb file 5NZS) was performed [11].
This splice site mutation lies in the trunk domain β-
COP but not at the ARF1 binding site. It leads to exon 8
skipping which causes a 108-bp deletion, and an in-
frame deletion of 36 amino acids, resulting in the loss of
a helix-turn-helix motif from the alpha solenoid struc-
ture (trunk) of β-COP (see Fig. 3b). It is noteworthy that
this lost motif in the β-COP trunk lies at a small inter-
face between β-COP and β’-COP (COPB2) (Fig. 3c).
This is one of the linking points between the adaptor
and scaffold coat subcomplexes composing the COPI
complex.
To verify bioinformatic predictions, RT PCR, gel elec-
trophoresis and Sanger sequencing of COPB1 amplicons
were performed on cDNA produced from blood-
extracted RNA from a homozygote and heterozygote.
Both the homozygous proband (IV2) and the heterozy-
gous parent (III1) cDNA amplified 2 bands (A and B)
(Fig. 2c). Sequencing of these bands showed that in both
the proband and parent, band B was a PCR amplicon
from a transcript with in-frame skipping of exon 8. Band
A in the parent was a PCR amplicon of the wild-type
transcript with exon 8 inclusion, whereas band A in the
proband was a PCR amplicon of a mutant transcript in
which exon 8 was included with a 1-bp deletion of
c.958G. This causes a frameshift, leading to a new in-
frame stop codon (TAA) 18 bp downstream of this dele-
tion (and 18 bp downstream of the junction between
exon 7 and exon 8). The mechanism through which this
mutant transcript escapes nonsense-mediated decay
(NMD) in the homozygote proband may be related to
the fact that the premature stop codon is only 18
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nucleotides downstream of the exon7/exon8 junction, as
previous work has shown that premature stop codons
less than 50 nucleotides from an exon/exon boundary
escape NMD as they are not recognised by the exon
junction complex in the NMD pathway [46]. However,
why the transcript undergoes NMD in the heterozygote
parent (we did not observe this transcript in the parent)
is unclear.
Family 2
WGS was undertaken in all affected family members
and several unaffected relatives (8 individuals). Only one
appropriately segregating homozygous variant was iden-
tified, underpinning the power of sequencing multiple
family members in large pedigrees [23]. The identified
mutation was a homozygous COPB1 missense variant,
c.1651T>G in exon 14 causing a Phe551Val amino acid
substitution (Chr11(GRCh37):g.14496127A>C), falling in
the β-COP-trunk domain (Fig. 3a). This variant was pre-
dicted by PolyPhen 2 to be probably damaging, predicted
by SIFT to be deleterious and predicted by CADD
(PHRED score) to be deleterious, scoring 32 (Table 3)
[39–42].
Phe551 is a highly conserved residue, conserved from
human to C. elegans and S. cerevisiae (Fig. 3b), with a
high PhyloP score of 5.21(− 14.1;6.4), modest Grantham
score at 50 (0–215) and high ConSurf score of 8/9. Al-
lele frequency was assessed using the gnomAD database.
The Family 2 variant (c.1651T>G, p.Phe551Val) was
absent.
Modelling of this mutation onto the 3D structure of β-
COP protein in complex with other components of the
COPI was performed [11]. This showed that the
mutation falls within the trunk domain, but lies distant
to its binding site with ARF1 and COPI subunits (Fig.
3c). Its significance is more likely to be its effect on in-
ternal β-COP structural integrity. Phe551Val lies at a
turn or a loop connecting two alpha helices which may
influence the directionality of the following helix or the
folding of the protein (Fig. 3d). Further functional work
was undertaken to investigate these predictions, see the
“Modelling of Family 2 missense variant” section.
copb1 disruptions in X. tropicalis
In order to investigate the phenotypic effect of β-COP
truncation, we used CRISPR/Cas9 to introduce inser-
tions and deletions (indels) into genomic copb1 in the
western clawed frog X. tropicalis at a site adjacent to the
genomic location of the variant found in participating
Family 1. There is now a large body of evidence showing
that making targeted indels in the western clawed frog is
so efficient that it is possible to analyse the resulting
phenotypes in founder animals [47–53]. This results in
robust but more rapid testing of the causality of a gene
variant in disease than waiting for F1 or F2 animals to
be available. The human and X. tropicalis copb1 genes
share exon structures in the updated frog genome (v10,
Xenbase), their COPB1 proteins are > 95% identical (Fig.
3d, Additional File 1: Fig. S1a) and both regions contain-
ing the patient variants are conserved.
To mimic the Family 1 human genomic change in
Xenopus as closely as possible (Family 1; exon 8),
sgRNAs were designed to create double-stranded DNA
breaks (DSBs) at the end of exon 8 in X. tropicalis copb1
(Fig. 4a, b). Analysis of the target genome region of mo-
saic, crispant embryos showed both skipping of exon 8
Table 3 Variants identified
Variant/family
no.





Donor site loss (− 26.84)
Splice Site Prediction by
Neural Network Donor site
loss (Mutant score = 0)
MaxEntScan
Donor site loss (− 78.36)
SpliceAI
Donor site loss
New donor site created













SIFT Deleterious Amino acid
conservation





The variant identified in Family 1 affects the +1 donor position of exon 8. Note the results from SpliceAI which predicts both donor site loss and creation of a new
donor site (verified by experimental data in Fig. 2). The missense variant in Family 2 is predicted to be deleterious by a number of tools
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Fig. 3 (See legend on next page.)
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and indels in exon 8 (Fig. 4c, d, Additional file 1: Figure
S1) and that both the eyes and the remainder of the tad-
pole were equally mosaic (Additional file 1: Figure S2).
RT-PCR from two separate sets of embryos showed that
there was a significant, consistent level of exon skipping
across injected embryos (Fig. 4d, Additional file 1: Figure
S1). Sanger sequencing of RT-PCR products confirmed
the expression of several different transcripts from the
targeted region, including transcripts in which exon 8 is
skipped, and transcripts in which exon 8 is retained but
which contain deletions and insertions (Additional file 1:
Figure S1(C,D)). Sequencing of PCR products from gen-
omic DNA from single tadpoles confirmed that the level
of mosaicism was high, few cells retained the unaltered
DNA sequence at the targeted locus (Additional file 1:
Figure S2). PCR products of the CRISPRed locus were
subcloned and individually sequenced, showing that a
series of deletions had occurred ranging from 5 to 41 bp
(Fig. 4c). These large deletions extended well into the in-
tron and were associated with the embryos showing
exon 8 skipping.
Two sgRNAs targeted the exon and each produced
identical phenotypes in independent experiments,
showing that the phenotype was not due to off-target
DSBs. Comparing the images from Fig. 5d, g and j with
those from Additional file 1: Figure S3 for the crispants
makes this clear, with unilateral cataracts, microcephaly
and occasional anophthalmia in both sets of tadpoles.
The chosen sgRNA(s) were tested for potential off-target
sites using CRISPRScan and Cas-OFFinder, neither de-
tected any significant hits. Since these programmes both
use previous versions of the genome, we repeated this
process manually using BLAST on X. tropicalis genome
version 10. In this case, a single potential off-target site
was detected, but in an intergenic region. Together with
the experimental evidence above, this shows that the ob-
served phenotype is due to cutting of the target locus.
We compared the effects of introducing indels into
exon 8 with those of introducing indels into exon 3
(Additional file 1: Figure S4(B,C)), where we hypothe-
sised the effect of truncating the protein would be a
more complete knockout, whether by nonsense-
mediated decay of the copb1 transcript or by an earlier
truncation of the protein. When introduced into exon 3
rather than 8, indels were more damaging to the embryo
as evidenced from the survival curve (Fig. 5o) and
(See figure on previous page.)
Fig. 3 Structure and conservation of COPB1 protein, and structural effect of missense variants. a Simple schematic diagram of COPB1 (β-COP)
structure showing two main structural domains; trunk domain and appendage domain, and relative location of the c.957+1G>T and p.Phe551Val
variants located towards the N terminal of the trunk domain. b COPB1 (β-COP) structure with the location of the 12 amino acids (in red) which
are deleted due to exon 8 skipping caused by c957+1G>T. c COPB1 (β-COP) structure in context of COPI complex. Note exon 8 (red) makes up
an important link between the scaffold and adaptor subcomplexes. d Alignment of COPB1 amino acid sequence from H. sapiens to yeast
showing very high conservation of Phe551 across all species tested. e 3D structural modelling of COPB1 in complex with COPB2 and COPG1
showing the location of Phe551 near the site of interaction with COPG1. f Higher resolution image showing the location of Phe551Val mutation
in a turn in the trunk domain
Fig. 4 Targeted CRISPR/Cas9 disruption of copb1 exon 8 generates a range of insertion-deletion changes in vivo. Xenopus tropicalis copb1 has 21
exons, including an untranslated first exon (a). CRISPR/Cas9 directed indel formation disrupting X. tropicalis exon 8 using 2 sgRNAs (red: sgRNA3
and sgRNA4 (b)) results in homozygous frameshift and splice changes akin to those identified within the patient subpopulation. Genotyping
analysis of X. tropicalis crispants details the range of indels across three groups of 10 pooled tadpoles (NF41) injected with sgRNA3 following PCR
amplification and Sanger sequencing of subclones (c). The 41-bp deletion observed in gDNA subclones extends into the intronic region and is
proposed to induce exon 8 skipping in crispant X. tropicalis tadpoles. Total RNA was obtained from 4 groups (un-injected control (1), copb1
sgRNA 3 crispant set 1 (2) and copb1 sgRNA 3 crispant set 2 (3), injected control (4)) of 10 pooled individuals as outlined in Guille 1999 [51] and
cDNA synthesised using Primer Design’s Reverse Transcription Premix 2. Amplification across the copb1 region of interest revealed a band at 382
bp (exons: 7, 8 and 9) and an additional band in crispants at 262 bp (exons: 7 and 9, Additional file 1: Fig. S1D)
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Fig. 5 F0 free-feeding wild-type and transgenic [Xtr.Tg (tubb2b:GFP) Amaya, RRID: EXRC_3001] Xenopus tropicalis crispants phenocopy key clinical
hallmarks. Images show tadpole head structural morphology under normal conditions (a–c) and across the range of phenotypes observed: mild
microcephaly (d–f), microcephaly with cataract(s) (g–i) and microcephaly with absent or missing eye structure(s) (j–l). White arrows on GFP
fluorescence images show normal forebrain structures in un-injected control animals (b) and altered forebrain structures in mutants, with an
increasing severity of microcephaly (e, h, k). Red arrows demonstrate the same forebrain structural trends in higher resolution MicroCT imaging
(1% phosphotungstic acid contrast stain: c, f, i, l). Cataract formation is indicated in bright-field and MicroCT images by yellow arrows (g, i) and
can be seen as a loss of GFP expression in fluorescence imaging (h), whilst green arrows highlight absent or missing structures of the eye (j, l).
Re-occurring eye abnormalities were documented in 30 un-injected and 30 crispant tadpoles (exon 8, sgRNA3) to show the prevalence of
cataract formation (mean, 14 tadpoles) and missing eye structures (mean, 5 tadpoles (m)). Further, 8 transgenic X. tropicalis crispant tadpole brains
were imaged and measured (mm) 3 days post-fertilisation (control mean 1mm, SD 0.02; Crispant mean 0.845 mm, SD 0.12 (t = 3.701; p = 0.007))
and 5 days post-fertilisation (control mean 6.37 mm, SD 0.29; Crispant mean 5.34 mm, SD 0.20 (t = 8.317; p = 0.000)) revealing sustained,
significant reduction in brain length. Brain length measured as the distance from the forebrain to the hindbrain (Additional file 1: Fig. S5a) was
expressed as a percentage of the mean of the control (N). Kaplan-Meier survival analysis of 50 un-injected control (median survival time 4.4 days)
and crispant X. tropicalis tadpoles, injected at the one-cell stage with either sgRNA1 (exon 3 (Additional file 1: Fig. S4, median survival time 2 days)
or sgRNA3 (exon 8, median survival time 3 days) show a significant difference in survival by log-rank comparison p = 0.000 (o)
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images of the affected embryos (Additional file 1: Figure
S4A). Whilst we cannot formally exclude the possibility
that more out of frame indels occur in exon 3 than in
exon 8, thus leading to the increased effect observed, the
limited sequence data available (Fig. 4c and Additional
file 1: Figure S4D) do not support this hypothesis
strongly.
All experiments were replicated in embryos from at
least three different females and the phenotype data
shown are from embryos injected with CRISPR/Cas tar-
geting exon 8 in one cell of a dividing, two-cell embryo.
This results in the effect of the protein truncation or in-
ternal deletion being focused on one side of the injected
embryo along the left-right axis with the other half act-
ing as an internal control [38]. Detailed labelling of
structures in tadpoles visualised using MicroCT and in
the fluorescent tadpole brain are shown in Additional
file 1: Figure S5. The crispants showed a range of de-
formities, including mild forebrain phenotypes that were
only visible in transgenically labelled brains or by
MicroCT imaging (Fig. 5): compare the forebrain struc-
tures shown by the white arrows in Fig. 5b with Fig. 5e
and the red arrows in Fig. 5c with Fig. 5f. More obvious
phenotypes include clear microcephaly in 27/30
crispants compared with 2/30 controls (telencephalon to
cerebellum length for controls median 0.995 mm ±
range of 0.03 mm; crispants median 0.855 mm ± range
0.17 mm; see Fig. 5n). Also, compare the neural struc-
tures highlighted by white arrows in Fig. 5b with those
in Fig. 5h and Fig. 5k and the red arrows in Fig. 5c with
those in Fig. 5i and Fig. 5l. Cataracts or anophthalmia
were also observed in 19/30 embryos but were absent in
controls (Fig. 5m; highlighted by the yellow arrows in
Fig. 5g and i) and revealed by the loss of the fluores-
cence from the transgenic marker crystallin-GFP in the
lens (compare the close-up images of the eyes in Fig. 5b,
h). The most extreme phenotypes have a wide range of
deformities that include almost complete loss of the eye
(see the green arrow in Fig. 5j, l). The few surviving em-
bryos when the gene was disrupted by indels in exon 3
also showed similar, but generally more exaggerated
phenotypes (Additional file 1: Figure S4(a,d)). As with
the human presentation, the phenotype was specific
when taken as a whole, but variable on the individual
level.
Modelling of Family 2 missense variant
We hypothesised that the Family 2 variant (c.1651T>G,
p.Phe551Val) affects the local structures and folding of
β-COP, which could affect its overall affinity of interac-
tions within COPI complex and undertook in vitro ana-
lysis to assess this further.
Mutant COPB1 cmyc-DDK-tagged plasmids were
generated using site-directed mutagenesis and
successful mutagenesis was confirmed using Sanger
sequencing. These plasmids were transfected into
HEK293 cells, which were then treated with 10 μg/ml
cycloheximide to inhibit protein synthesis to provide
a more robust test of protein stability. Cells were
lysed and protein extracted after 16 h and analysed by
SDS PAGE and western blotting. Only a very subtle
difference between β-COP-cmyc band intensity was
observed between WT and mutant protein (Fig. 6a).
Densitometry analysis revealed that relative, normal-
ised levels of β-COP c.1651T>G p.Phe551Val (nor-
malised to beta actin loading control) were lower
than β-COP WT levels, suggesting a mild reduction
in protein stability of the mutant β-COP (Fig. 6a).
Plasmids were also transfected into hTERT RPE-1 cells
and after 48 h the Golgi was stained with BODIPY-TR-
ceramide and cells were fixed and β-COP-cmyc was im-
munostained with anti-cmyc. Confocal microscopy im-
aging showed a subtle change in localisation of mutant
β-COP compared to WT β-COP. Whilst WT β-COP
could be seen in a defined pattern at the Golgi, mutant
β-COP could be seen in a more diffuse location (Fig.
6b), suggestive of a defect in Golgi to ER recycling of the
COPI complex. To investigate this further, we repeated
transfections and immunostained the Golgi membrane
with an antibody to giantin, which is a protein integral
to the Golgi membrane, and co-immunostained with an
antibody to β-COP. This showed again that β-COP
c.1651T>G p.Phe551Val is more widely distributed
throughout the cell, but also more widely distributed
throughout the Golgi (Fig. 6c). Whereas wild-type β-
COP localised specifically to the edges of the Golgi
stacks, mutant β-COP is localised throughout the Golgi,
as can be seen by the greater overlap of green (giantin)
and red (β-COP) staining, which appears yellow (Fig.
6c). Staining of the ER with anti SERPINH1 showed no
difference in localisation of wild-type β-COP and β-COP
c.1651T>G p.Phe551Val relative to the ER (Additional
file 1: Fig. S6). Together, these data suggest that β-COP
c.1651T>G p.Phe551Val is defective in Golgi to ER re-
cycling, with this mutant β-COP getting retarded in the
Golgi.
Discussion
In this paper, we present a new syndrome characterised
by severe developmental delay and cataracts with the
majority of patients also being microcephalic. Family 2
also exhibits spasticity and immunodeficiency, whereas
Family 1 demonstrates a “metabolic syndrome” pheno-
type from late childhood. Our model reflects this highly
heterogenous phenotype with some Xenopus showing
neither microcephaly nor cataracts, with others being se-
verely affected. Our in silico and in vitro missense
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modelling work demonstrates a high conservation of the
specific residue (c.1651T>G p.Phe551Val) mutated in
this family and an impact on localisation of protein with
this specific mutant residue observed in cells, with this
mutant protein being retarded in the Golgi. Given that
the primary role of COPI is to return ER-resident mole-
cules from the Golgi, the localisation abnormality seen
associated with the expression of the missense construct
is likely to have a significant effect on normal function-
ing of the endomembrane system. As the splice variant
Fig. 6 Effect of expression of COPB1 mutation on in vitro localisation and stability of β-COP protein. a Western blot image of protein extracts
from HEK293 cells transfected with wild-type, and c.1651T>G (COPB1 tagged with c-myc, immunoblotted with c-myc antibody to detect COPB1,
and with beta-actin antibody as loading control). c.1651T>G shows a slightly reduced normalised level. b Immunofluorescence images of hTERT-
RPE1 cells nucleofected with wild-type COPB1 (top row), and COPB1 c.1651T>G p. p.Phe551Val (lower row) tagged with c-myc. Cells were stained
with Golgi stain Bodipy-TR-ceramide (red), nuclear stain DAPI (blue) and immunostained with anti-myc (green). Mutant expression shows more
diffuse β-COP staining throughout the Golgi and outside the Golgi in the wider cytoplasm. Scale bar = 5 μm. c Immunofluorescence images of
hTERT-RPE1 cells nucleofected with wild-type COPB1 (top row), and COPB1 c.1651T>G p. p.Phe551Val (lower row) tagged with c-myc. Cells were
stained with nuclear stain DAPI (blue) and immunostained with an antibody to resident Golgi protein giantin (green) and anti-β-COP (red). This
clarified that wild-type β-COP tended to localise to the edges of the Golgi stacks, whereas mutant β-COP was localised throughout the Golgi.
Scale bar = 10 μm
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in Family 1 causes skipping of a 108-bp exon, leading to
an in-frame deletion of 36 amino acids in the protein,
we hypothesise that both the missense and splice vari-
ants are hypomorphs which retain some functionality.
We further hypothesise that null alleles may be embry-
onically lethal in mammals, as for other some coatomer
subunits [3, 4]. This hypothesis is supported by data
from Xenopus in which frameshift indels in exon 3 of
copb1 were introduced mosaically using CRISPR/Cas.
Survival rates were very low in these knockout animals
and survivors’ phenotypes similar to, but generally more
severe than those in embryos carrying indels in exon 8.
Microcephaly was a prominent phenotype in this syn-
drome and clearly reproduced in the Xenopus model. A
homozygous variant in the related COPB2 (β’-COP) has
been linked to a primary microcephaly syndrome [4].
The authors describe siblings with microcephaly, failure
to thrive, spasticity, cortical blindness and severe devel-
opmental delay, which share some obvious similarities
to, in particular, Family 2 in our study. ARCN1-related
syndrome (δ-COP) also includes features of microceph-
aly and, albeit milder, developmental delay. Interfering
RNA screens indicate that COPB1 may play an import-
ant role in cell division which could be linked to the
microcephaly seen in these patients [54]. Previous stud-
ies have indicated that COPI has numerous roles in
neuronal function. For example, it may play a role in the
transport of RNA in neurons and is also involved in the
transport of SNARE complex proteins which traffic neu-
rotransmitters [55, 56]. Interferonopathies are a known
cause of microcephaly, and notably a recent study inves-
tigating the protein network of interferon-stimulated
genes identified β-COP as one of the two most con-
nected proteins in this network of 1400 [57].
All affected individuals in this study had markedly
delayed gross motor milestones. Interestingly, COPI (in-
cluding β-COP) interacts with the protein Staismon
which is thought to be important in synaptic transmis-
sion in motor circuit neurons and in motor axon
outgrowth [58]. Additionally, COPI, through its subunit
α-COP, binds with survival motor neuron protein
(SMN), which is deficient in spinal muscular atrophy
(SMA) and is involved in its axonal transport [59]. Fur-
thermore, SMA patients show abnormal Golgi apparatus
morphology which can be corrected by overexpression
of α-COP [60].
Six of six individuals identified in this study have de-
veloped cataracts. Interestingly, the cataracts in Family 1
developed quite late in childhood, which is a less com-
mon presentation for congenital cataracts. Several other
coatopathies demonstrate cataracts in their phenotype.
For example, cranio-lenticulo-sutural dysplasia has been
linked to homozygous variants in the COPII gene
SEC23A. These patients had a missense mutation in
SEC23A (use italics for this word please) which, when
exogenously expressed in cells in culture, displayed a
cellular phenotype suggestive of abnormal Golgi to ER
trafficking [61]. The pathogenesis of this phenotype is
unclear.
Family 2 exhibits the additional phenotype of im-
munodeficiency; this was absent from Family 1 who have
had normal immunology studies. Given the role of coat
proteins in the secretory pathway, we hypothesise altered
immune function may be, at least in part, due to the
high demand of plasma cells on protein (immunoglobu-
lin) expression, modification and secretion. Additionally,
β-COP is listed as a secretory granule membrane protein
with a role in neutrophil degranulation on reactome
database [62]. We also note the role of β-COP in MHC1
and CD4 degradation in HIV-infected cells [63, 64]. It is
also possible that the additional feature of immunodefi-
ciency and spasticity may be due to an as yet unidenti-
fied second variant in this highly selected family though
no appropriate candidates were identified on extensive
review.
Conclusions
In conclusion, we have described a novel recessive syn-
drome caused by biallelic variants in COPB1. Disrupting
copb1 in Xenopus clearly shows phenotypic changes in
common with the patients, in particular microcephaly
and cataracts, strongly supporting the link between the
patient variants and their pathology. The utility of these
data in making the connection between the gene change,
including exon skipping, and phenotype is another dem-
onstration of how successful X. tropicalis is as a tool for
the characterisation of novel disease genes. Taken to-
gether, our data add to the growing body of evidence
that COPI subunits are essential for brain development
and human health.
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